

# Guidelines for the use of tumour markers



ACBI  
Scientific  
Committee  
Guidelines

# Guidelines for the use of tumour markers

Association of Clinical Biochemists in Ireland

MJ Duffy P McGing

Produced by the  
Scientific Committee  
of the  
Association of Clinical Biochemists in Ireland  
(ACBI)

Fourth edition: October 2010

ISSN 2009-3977

Other booklets in this series

Guidelines on the use of biochemical cardiac markers and risk factors

Guidelines on the use of therapeutic drug monitoring

The biochemistry of body fluids

## Contents

Preface	vii
Introduction	1
General References on Tumour Markers	3
Alpha-Fetoprotein (AFP)	4
CA 125	6
CA 15-3	8
CA 19-9	10
CEA	12
Human Chorionic Gonadotropin (hCG)	14
Prostate Specific Antigen (PSA)	16
Free PSA (fPSA)	20
Use of Serum Markers in Diagnosing Cancer of Unknown Primary Origin (Occult Cancers)	23
Tissue Markers in Breast Cancer	24
Estrogen and Progesterone Receptors (ER and PR)	24
HER-2 (c-ErbB-2)	25
Urokinase Plasminogen Activator (uPA) and PAI-1	26

## Preface

This is the 4<sup>th</sup> edition of the well established publication 'Guidelines for the use of Tumour Markers' and is part of a series commissioned and produced by the Scientific Committee of the Association of Clinical Biochemists in Ireland to promote appropriate and effective use of the laboratory service. It is intended to be a concise reference document to assist both practitioners in the Clinical Biochemistry field and those who are users of the laboratory service.

The guidelines in this new edition are based upon up to date scientific evidence and expert consensus and will provide support for consistency of test requesting. There is also a new section outlining the use of Tumour Markers in patients with a cancer of unknown primary origin and it is hoped that this section will provide useful guidance in what is considered a difficult clinical management situation.

On behalf of ACBI Council, I would like to express our gratitude to the Scientific Committee and the individual authors for their work on this project. In particular, we are honoured to have Prof Joe Duffy as the lead author. Prof Duffy has published extensively in this field and has been a lead contributor to major international guidelines for the use of Tumour Markers. Council is also grateful to Cruinn Diagnostics Ltd and Siemens Ltd for their generous financial contribution to the printing costs of this new edition.

Ms Orla Maguire,  
President, ACBI

October 2010

## Introduction

The purpose of this booklet is to give a brief background to enable the judicious use of seven widely performed serum cancer markers. The format used here is similar to that in previous editions. However, in this 4<sup>th</sup> edition, we provide for the first time, a section on the use of serum markers in the diagnosis of tumours of unknown primary origin

While this booklet gives specific details relating to the most frequently used markers, we feel that it is important to make some general points about tumour marker tests.

- No serum marker in current use is specific for malignancy.
- Generally, serum marker levels are rarely elevated in patients with early malignancy. With a few exceptions, high levels are usually found only when patients have advanced disease.
- No cancer marker has absolute organ specificity. PSA however, appears to be relatively specific for prostate tissue, but not for prostate cancer.
- Apart from possibly hCG in choriocarcinoma, no marker is elevated in 100% of patients with a particular malignancy.
- Requesting of multiple markers (such as CEA and the CA series of antigens) in an attempt to identify metastases of unknown primary origin is rarely of use (see below).
- Tumour markers assays should not be carried out on biological fluids such as peritoneal fluids, pancreatic juice and ovarian cystic fluids as reliable reference ranges are currently unavailable for these types of specimen.
- Reference ranges for cancer markers are not well defined and are used only for guidance. Please note that a level below the reference range does not exclude malignancy while concentrations above the reference range does not necessary mean the presence of cancer. Changes in levels over time are likely to be more clinically useful than absolute levels at one point in time.
- As many tumour markers lack agreed International Reference Preparations (e.g CA125, CA15-3, CA19-9), different assay kits may give different results for the same sera.
- Laboratories carrying out tumour marker tests should state the assay used on their report form.

## General References on Tumour Markers

1. Duffy MJ. Clinical uses of tumor markers: a critical review. *Crit Rev Clin Lab Sci* 2001;38:225-262.
2. Duffy MJ. Role of tumor markers in patients with solid tumors: a critical review. *Eur J Int Med* 2007;18:175-184.
3. Sturgeon CM, Lai LC, Duffy MJ. Serum tumor markers: how to order and interpret them. *Br Med J* 2009;339:852-858.
4. Sturgeon CM, Duffy MJ, Stenman U, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast and Ovarian Cancers. *Clin Chem* 2008;54:e11-e79.
5. Sturgeon C, Duffy MJ, Hoffman, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers. *Clin Chem* 2010;56:e1-e48.

## Alpha-Fetoprotein (AFP)

### Structure

AFP is a 70 kDa glycoprotein homologous to albumin.

### Forms in serum

AFP exhibits microheterogeneity probably due to varying levels of glycosylation. AFP produced by malignancies appears to be more highly fucosylated than that formed by normal tissues.

### Physiological function

Appears to perform some of the functions of albumin in the foetal circulation.

### Malignancies with elevated levels

Mainly confined to 3 malignancies, i.e.

- a. Non-seminomatous germ cell tumours (NSGCT) of testis, ovary and other sites.
- b. Hepatocellular carcinoma (HCC).
- c. Hepatoblastoma (in children, extremely rare in adults).
- d. AFP may be occasionally elevated in patients with other types of advanced adenocarcinoma.

### Benign conditions which may have elevated levels

Hepatitis, cirrhosis, biliary tract obstruction, alcoholic liver disease, ataxia telangiectasia and hereditary tyrosinaemia.

### Physiological conditions with elevated levels

Pregnancy and the first year of life. Infants have extremely high levels which fall to adult values between 6 months and 1 year of age. A slower than normal rate of fall may indicate the presence of a tumour.

### Main clinical applications

- a. In combination with hCG, for monitoring patients with NSGCT (mandatory).
- b. Independent prognostic marker for NSGCT (e.g. of the testis).
- c. Diagnostic aid for hepatocellular carcinoma and hepatoblastoma. In patients with cirrhosis and a focal lesion > 2 cm with arterial hypervascularization, an AFP level >200 µg/L is suggestive of HCC, and AFP>400 µg/L is strongly suggestive of HCC.
- d. Screening for hepatocellular carcinoma in high risk populations (e.g. in patients with cirrhosis due to hepatitis B or C). Surveillance is

recommended using 6-monthly AFP measurement and abdominal ultrasound, with AFP>20 µg/L and rising prompting further investigation.

- e. Note that AFP is not a useful marker for liver metastases. For liver metastases, CEA is preferable marker.

### Reference range

0 - 10 kU/L or 0-12 µg/L

### Half life in serum

Approx. 5 days.

### Comment on assay

Existing immunoassays appear to detect total AFP and do not discriminate between different glycosylated forms.

### References

1. International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. *J Clin Oncol* 1997;15:594-603.
2. Bruix J, Sherman M. Management of hepatocellular carcinoma. *Hepatology* 2005;42:1208-36.
3. Sturgeon C, Duffy MJ, Hoffman, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers. *Clin Chem* 2010;56:e1-e48.

## CA 125

### Structure

CA 125 refers to the antigen originally detected by the OC-125 antibody. The protein detected by this antibody is Muc16, a mucin with a single transmembrane domain.

### Forms in serum

The major forms in serum have molecular weights of 200 kDa to 400 kDa.

### Physiological function

None established.

### Malignancies with elevated levels

- a. Epithelial ovarian cancer; 80 - 85% of all cases; but increased in only half of early (stage 1) cancer.
- b. May be elevated in any adenocarcinoma with advanced disease.

### Benign conditions which may have elevated levels

Endometriosis, acute pancreatitis, cirrhosis, peritonitis, inflammatory pelvic disease. The presence of ascites (of non-malignant origin) can also give rise to elevated serum levels of CA 125.

### Physiological conditions with elevated levels

Menstruation and pregnancy may be associated with moderately elevated serum CA 125 (usually not more than 100 kU/L)

### Main clinical applications

- a. While CA125 should not be used in screening asymptomatic women for sporadic ovarian cancer, its measurement in postmenopausal patients with pelvic masses may help differentiate malignant from benign lesions.
- b. The rate of decline during initial therapy is an independent prognostic indicator in ovarian carcinoma.
- c. Monitoring treatment with chemotherapy.
- d. Surveillance following initial treatment. The impact of this on survival is unclear.

### Type of sample for assay

Serum is recommended.

CA 125 may be assayed on other fluid samples (e.g. ascitic fluid) but this cannot be recommended (outside of research projects), on analytical and interpretational grounds.

### Reference range

0 - 35 kU/L (most frequently used range).

Please note however, that levels may be higher in premenopausal than postmenopausal women.

### Half life in serum

Approx. 5-7 days.

### References

1. Duffy MJ, Bonfrer JM, Kulpa J, et al. CA 125 in ovarian cancer: European Group on Tumor Markers (EGTM) guidelines for clinical use. *Int J Gynecol Oncol* 2005;15:679
2. Tuxen MK, Soletormos G, Dombernowsky P. Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy. *Br J Cancer* 2001;84:1301-1307.

## CA 15-3

### Structure

CA 15-3 is a transmembrane glycoprotein encoded by the MUC1 gene. It is defined by reactivity with 2 monoclonal antibodies, i.e., DF3 and 115D8 in a sandwich immunoassay.

### Physiological function

May be involved in cell adhesion and cancer pathogenesis.

### Malignancies with elevated levels

Breast and other adenocarcinomas, especially with distant metastasis. Rarely elevated in patients with local breast cancer.

### Benign diseases with elevated levels

Benign liver disease, possibly benign breast disease.

### Main clinical applications:

- a. For preclinically detecting recurrences in asymptomatic patients with diagnosed breast cancer. Use of CA 15-3 in this setting is controversial.
- b. For monitoring the treatment of patients with advanced breast cancer, especially in patients with disease that cannot be evaluated using standard criteria.

### Reference range

0 – 25 to 0 – 40 kU/L

### Half life in serum

Unknown

### Comment about assay

Other assays such as BR 27.29 appear to measure the same antigen as CA 15-3

### References

1. Duffy MJ. CA 15-3 and related mucins as markers in breast cancer: a critical review. *Ann Clin Biochem* 1999;36:579-586.
2. Duffy MJ. Serum tumor markers in breast cancer: are they of clinical value? *Clin Chem* 2006;52:345-51.
3. Molina R, Barak V, van DA, Duffy MJ, Einarsson R, Gion M, et al. Tumor markers in breast cancer - European Group on Tumor Markers recommendations. *Tumour Biol* 2005;26:281-93.
4. Harris L, Fritsche H, Menel R, Norton L, Ravidin P, Taube S, et al. American Society of Clinical Oncology 2007 Update of recommendations for the use of tumor markers in breast cancer. *J Clin Oncol* 2007;25:5287-312.

## CA 19-9

### Structure

A mucin which reacts with monoclonal antibody 111 6 NS 19-9.

### Physiological function

May be involved in cell adhesion.

### Malignancies with elevated levels

Most pancreatic adenocarcinomas, approx. 50% of gastric carcinomas and approx. 30% of colorectal carcinomas.

### Benign conditions which may have elevated levels

Acute and chronic pancreatitis, hepatocellular jaundice, cirrhosis, acute cholangitis and cystic fibrosis.

### Main clinical applications

- a. As a diagnostic aid for pancreatic carcinoma. Inadequate sensitivity and specificity limit the use of CA 19-9 in the early diagnosis of pancreatic cancer. However, in non-jaundiced patients, CA 19-9 may complement other diagnostic procedures.
- b. Monitoring treatment of patients with pancreatic adenocarcinoma.

### Other potential uses

Diagnostic aid in gastric and cholangio carcinomas. For colorectal cancer, CEA is generally more valuable than CA 19-9.

### Reference range

Very variable, from 0 - 37 kU/L to 0 - 100 kU/L

### Half life in serum

Approx. 1 day but can vary from less than 1 day to 3 days.

### References

1. Duffy MJ. CA 19-9 as a marker for gastrointestinal cancers. *Ann Clin Biochem* 1998;35:364-370.
2. Duffy MJ, Sturgeon C, Lamerz R, et al, Tumor Markers in Pancreatic Cancer: A European Group on Tumor Markers (EGTM) Status Report. *Ann Oncol* 2010;21:441-447.

## CEA

### Structure

A 200 kDa (approx.) glycoprotein.

### Physiological function

Appears to play a role in cell adhesion and inhibition of apoptosis.

### Malignancies with elevated levels

Can be elevated in almost any advanced adenocarcinoma, i.e., where distant metastases are present. Almost never elevated in early malignancy.

### Benign diseases which may have elevated levels

Hepatitis, cirrhosis, alcoholic liver disease, obstructive jaundice, ulcerative colitis, Crohn's disease, pancreatitis, bronchitis, emphysema and renal disease. Levels may also be mildly elevated in apparently healthy individuals who smoke.

### Physiological conditions with elevated levels

None to our knowledge.

### Main clinical applications

- a. In surveillance following curative resection of colorectal cancer.
- b. In monitoring therapy in advanced colorectal cancer. This is especially important when disease cannot be evaluated by standard criteria.

### Other potential uses

May also be useful in other gastrointestinal malignancies and as a "general purpose" marker for adenocarcinomas. Please note however, that CEA is rarely elevated in patients with any type of local cancer.

### Reference range

0 - 3.5 µg/L to 0 - 5.0 µg/L.

### Half life in serum

Approx. 3 days but can vary from 1 to 5 days.

### References

1. Duffy MJ. CEA as a marker for colorectal cancer: is it clinically useful. *Clin Chem* 2001;47:624-630.
2. Duffy MJ, van Dalen A, Haglund C. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumor Markers (EGTM) guidelines. *Eur J Cancer* 2003;39:718-727.
3. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. *J Clin Oncol* 2006;24:5313-27.
4. Duffy MJ, van Dalen A, Haglund C, Hansson, et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. *Eur J Cancer* 2007;43:1348-1360.

## Human Chorionic Gonadotropin (hCG)

### Structure

hCG is a heterodimer composed of 2 glycosylated sub-units (alpha and beta chains) non-covalently bonded. The alpha chain is almost identical to the alpha chain in TSH, FSH and LH. The beta chain is distinct from the corresponding chains in TSH and FSH but has a high degree of homology with LH over the first 75% of the amino sequence. hCG however, possesses a distinctive 24 amino acid carboxy-terminal extension.

### Forms in serum

hCG can exist in multiple forms including the intact 2-chain peptide, free alpha and beta chains, as well as various degradation products (e.g., beta core fragment).

### Physiological function

To maintain progesterone production by the corpus luteum during early pregnancy. hCG can be detected as early as one week after conception.

### Malignancies with elevated levels

- Virtually all patients with gestational trophoblastic disease (GTD) (i.e., complete and partial molar pregnancy, choriocarcinoma and placental site trophoblastic tumours).
- Non-seminomatous germ cell tumours (NSGCT) (e.g., of testis and ovary).
- Seminomatous germ cell tumours of testis (approx. 20%).
- Can be produced by a small number of other malignancies.

### Benign Diseases With elevated levels

Very few, e.g., ectopic pregnancy, pituitary adenoma.

### Physiological conditions with elevated levels

Pregnancy, after termination of pregnancy.

### Main clinical applications

- For monitoring patients with GTD.
- In conjunction with AFP, for determining prognosis and monitoring patients with NSGCT of testis, ovary and other sites.

### Other potential uses

Diagnostic aid for trophoblastic disease. Serum hCG levels do not usually differentiate between trophoblastic tumours and normal pregnancy. However, very high levels outside the range for twin pregnancies may lead to suspicion of a trophoblastic tumour. For diagnosing trophoblastic tumours, hCG assays are usually used in combination with ultrasound.

### Type of sample for assay

Serum or urine.

### Reference range

Serum: 0 - 5 IU/L.

### Half life in serum

Approx. 16 - 24 hours; decline may be biphasic with a second half life of 13 days.

### Comment about assay

When used as a tumour marker, assays for hCG should detect all the main forms, especially the intact molecule and beta-subunit.

Some hCG assays may give either false-positive or false-negative results. If false-positive results are suspected, then measure hCG in urine.

Note: some methods for hCG may cross-react with LH.

### References

- Sturgeon C and McAllister EJ. Analysis of hCG. Clinical applications and assay requirements. *Ann Clin Biochem* 1998;35:460-491.
- Stenman U-H et al. Human chorionic gonadotropin in cancer. *Clinical Biochem* 2004;37:549-561
- Cole LA. Human chorionic gonadotropin and associated molecules. *Expert Rev Mol Diagn* 2009;9:51-73.
- Sturgeon CM, Berger P, et al on behalf of the IFCC Working Group on hCG. Differences in recognition of the 1<sup>st</sup> WHO international reference reagents for hCG-related isoforms by diagnostic immunoassays for human Chorionic Gonadotropin. *Clin Chem* 2009;55:1484-1491.

# Prostate Specific Antigen (PSA)

## Structure

A 28.4 kDa single chain chymotrypsin-like serine protease containing 237 amino acids and a member of the glandular kallikrein family.

## Forms in serum

Various molecular forms because of complex formation with protease inhibitors. Major immunoreactive form is PSA complexed with  $\alpha_1$ -antichymotrypsin (PSA-ACT). Other complexes occur such as PSA linked to  $\alpha_1$ -antitrypsin (trace quantity) and  $\alpha_2$ -macroglobulin (undetectable by current immunoassays). A non-complexed free form (fPSA) represents 5 to 40% of the "total" PSA ( fPSA +  $\alpha_1$ -antichymotrypsin complex).

## Physiological function

Partially responsible for the liquefaction of semen to promote the release and motility of spermatozoa.

## Malignancy with elevated levels

Present data suggests that prostate cancer is the only malignancy giving rise to elevated PSA levels in serum. However, PSA has been found in cells from various cancer types and different normal tissues. PSA is thus not completely prostate specific.

## Benign conditions with elevated levels

Benign prostatic hypertrophy (BPH), acute and chronic prostatitis, UTI, urinary retention.

A number of urological manipulations such as TURP, prostate biopsy, prostate massage and ejaculation may give rise to transient elevated levels. See Section *Effects of Urological Manipulations on PSA Levels* on the next page.

## Physiological conditions with elevated levels

None described.

## Main clinical applications

- In combination with digital rectal examination PSA can aid the diagnosis of prostate cancer.
- Determining prognosis in patients with prostate cancer.
- Surveillance following diagnosis of prostate cancer
- Monitoring therapy in patients with diagnosed prostate cancer.

## Other potential uses

The value of PSA in screening for prostate cancer is controversial. Preliminary results from two randomized prospective trials were recently published. One trial found no significant reduction in mortality from prostate cancer, while the other found a 20% reduction in mortality, but at the expense of overdiagnosis.

## Reference range:

0 - 4  $\mu\text{g/L}$  (most frequently used) but some advocate age-related reference ranges as follows:

Age Range	PSA $\mu\text{g/L}$
40 - 49	0 - 2.5
50 - 59	0 - 3.5
60 - 69	0 - 4.5
70 - 79	0 - 6.5

## Half life in serum

Approximately 2.5 days after radical prostatectomy. Half life after radiotherapy may be many months.

## Effects of urological manipulations on PSA levels.

It is advisable to take blood for PSA measurement before rather than after any of these manipulations.

DRE	May cause minor increases which are rarely of clinical significance.
Prostate massage	May cause minor elevations in some patients.
Ejaculation	Results conflicting but may increase PSA levels.
TURP	Increases PSA levels significantly. It is recommended to wait at least 6 weeks before drawing blood for PSA assay.
Needle Biopsy	As with TURP, increases PSA levels significantly. Wait at least 6 weeks before drawing blood for PSA assay.
Ultrasound	Increases PSA levels in a minority of subjects.
Cystoscopy	Flexible cystoscopy does not appear to increase PSA levels but rigid cystoscopy may increase levels.

### Effect of drugs on PSA levels

Finasteride and Dutasteride, 5-alpha-reductase inhibitors used to treat BPH, reduce PSA levels by approx. 50%.

### Comment about assay

PSA assays should detect the free and complexed forms on an equimolar basis. Furthermore, the assay should be standardised against the First International Standard for PSA.

Total PSA is stable for at least 6 hours at room temperature in uncentrifuged clotted blood. Five cycles of freezing and thawing caused no significant change.

### References

1. Hernandez J, Thompson IM. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. *Cancer* 2004;10:894-904.
2. Han M et al. Prostate-specific antigen and screening for prostate cancer. *Med Clin N Am* 2004;88:245-265.
3. Sturgeon CM, Duffy MJ, Stenman UH, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. *Clin Chem* 2008;54:e11-79.
4. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. *N Engl J Med* 2009;360:1310-1319.
5. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. *N Engl J Med* 2009;360:1320-1328.
6. Barry, MJ. Screening for Prostate Cancer - The controversy that refuses to die (editorial). *N Engl J Med* 2009;360:1351-1354.

## Free PSA (fPSA)

### Form in serum

As stated above, PSA exists in serum in both a bound and free form. The free form includes enzymically inactive pre-PSA, pro-PSA, clipped-PSA and the enzymatically active form of free PSA. The lower the %fPSA, the higher the probability of prostate cancer.

### Main clinical applications

To enhance the specificity of total PSA in detecting prostate cancer, especially when total PSA values are between 4 and 10 µg/L. The use of free/total PSA in men with PSA levels can reduce the number of unnecessary biopsies.

### Type of sample for assay

Serum or plasma, assay should be carried out on same sample which had total PSA determined.

### Reference range

fPSA results can be used in 2 ways:

1. Use of a single cut-off point. In a large prospective multi-centre study with a cut off point of <25% fPSA (Ref 1), it was shown that unnecessary needle biopsies could be reduced by 20% while maintaining a 95% cancer detection rate with total PSA levels between 4 and 10 µg/L.
2. Probability of cancer: In the same multi-centre study, the following relationships were found between % fPSA and probability of prostate cancer.

% fPSA	% Cancer Probability
0-10	56
10-15	28
15-20	20
20-25	16
>25	8

### Comment about assay

When using %fPSA, both the free and total PSA assay should be obtained from the same supplier. fPSA is less stable than total PSA, for medium and long-term storage, freezing at -70°C is recommended. Assay of complex PSA, i.e. PSA bound to ACT, appears to give similar information to the free/total ratio in men with PSA levels between 2 and 10 µg/L.

### Effect of urological manipulations on fPSA

All the manipulations which increase total PSA levels also increase the level of free PSA as well as the percentage free.

### Effect of drugs

While certain 5-alpha-reductase inhibitors, such as Finasteride and Dutasteride, reduce both total and free PSA levels, they do not significantly change the %fPSA level.

### References

1. Chan DW et al. Analytical and clinical performance of Hybritech's Tandem-R free PSA assay during a large multi-center clinical trial to determine the clinical utility of percentage of free PSA. *Clin Chem* 1999;45:1863-5.
2. Woodrum DL et al. Interpretation of free PSA clinical research studies for the detection of prostate cancer. *J Urol* 1998;159:5-12.
3. Roddam AW, Duffy MJ, Hamdy FC, Ward AM, Patnick J, Price C, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. *Eur Urol*, 2005;48:386-99.

## Use of Serum Markers in Diagnosing Cancer of Unknown Primary Origin (Occult Cancers)

### Cancers of unknown primary

Cancers of unknown primary origin or occult cancers are defined as histologically proven malignant metastatic tumours whose primary origin cannot be identified during pretreatment evaluation.

### Overview of clinical utility

In general, serum markers are of little value in identifying the primary site. This is because, with a small number of exceptions, currently available serum markers are not organ-specific. Indeed, most of the available markers such as CEA, CA 125, CA 19-9 and CA 15-3 can be elevated in most types of advanced adenocarcinomas.

### Main clinical applications

Markers that are potentially useful in diagnosing or excluding a likely site are:

- PSA in men for including or excluding prostate cancer.
- AFP and hCG for including or excluding a germ cell tumour.
- Thyroglobulin for including or excluding a differentiated thyroid tumour.

### Reference

1. Sturgeon CM, Lai LC, Duffy MJ. Serum tumor markers: how to order and interpret them. *Br Med J* 2009;339:852-858.

## Tissue Markers in Breast Cancer

### Estrogen and Progesterone Receptors (ER and PR)

#### Clinical uses

- a. For predicting response to hormone therapy in patients with either early or advanced breast cancer.
- b. In combination with other factors, ER and PR may be used to determine prognosis.

#### Recommended assay

Immunohistochemistry with a validated antibody.

#### References

1. Duffy MJ. Biochemical markers in breast cancer: which ones are clinically useful. *Clin Biochem* 2001;34:347-352.
2. Duffy MJ. Predictive markers in breast and other cancers. *Clin Chem* 2005;51:494-503
3. Hammond MEH, Hayes DF, et al. American Society of Clinical Oncology-College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. *J Clin Oncol* 2010;28:2784-2795.

### HER-2 (c-ErbB-2)

#### Clinical uses

- a. Mandatory uses: For the identification of patients who may be treated with trastuzumab (Herceptin) in the metastatic setting, and to identify patients that may be eligible for clinical trials of trastuzumab in the adjuvant setting.
- b. In combination with other factors, HER-2 may also be used to determine prognosis.
- c. Insufficient data is currently available to recommend HER-2 for predicting response to endocrine therapy or any type of chemotherapy.

#### Recommended assay

- a. FISH or immunohistochemistry with validated antibodies and standardized methodology. For equivocal cases (i.e., those with scores of 2+), testing with FISH should be carried out.
- b. The extracellular domain of HER-2 can be measured in serum. Serum HER-2 levels may be used for post-operative surveillance and monitoring therapy in patients with breast cancer. Based on evidence presently available, use of serum HER-2 has no advantage over CA 15-3. It may however, be of use if CA 15-3 is not elevated. Preliminary findings suggest that serum HER-2 may be of value in monitoring Herceptin therapy.

#### References

1. Duffy MJ. Biochemical markers in breast cancer: which ones are clinically useful. *Clin Biochem* 2001;34:347-352.
2. Duffy MJ. Predictive markers in breast and other cancers. *Clin Chem* 2005;51:494-503.
3. Wolff AC, Hammond MEH, et al. American Society of Clinical Oncology-College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. *J Clin Oncol* 2007;25:118-145

## Urokinase Plasminogen Activator (uPA) and PAI-1

### Clinical uses

- a. Assay of uPA and PAI-1 can be carried out to identify lymph node-negative breast cancer patients that may not need, or who are unlikely to benefit from, adjuvant chemotherapy.
- b. The prognostic value of these factors for lymph node-negative breast cancer patients has been validated using both a randomised trial and a pooled analysis.

### Recommended assay

A validated ELISA

### References

1. Duffy MJ. Urokinase plasminogen activator and its inhibitor PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies.  
Clin Chem 2002;48:1194-1197.
2. Janicke F, Prechtel A, Thomssen C, Harbeck N, Meisner C, Sweep F, et al. For the German Chemo N<sub>0</sub> Study Group. Randomized adjuvant chemotherapy trial in high-risk node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.  
J Natl Cancer Instit 2001;93:913-920
3. Look MP, van Putten WLJ, Duffy MJ, et al. Pooled analysis of prognostic impact of tumor biological factors uPA and PAI-1 in 8377 breast cancer patients.  
J Natl Cancer Instit 2002;94:116-128.



ACBI  
Scientific  
Committee  
Guidelines